Please login to the form below

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

Amgen starts shipping Corlaner in US

Amgen starts shipping Corlaner in US. Firm also reports healthy financial growth in the first quarter. ... Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA approval for the drug.
FDA clears Amgen's Corlaner for heart failure

FDA clears Amgen's Corlaner for heart failure. It is the firm’ s first cardiovascular product to gain approval. ... Amgen's heart failure drug Corlaner has been given the green light by the US FDA, giving the company its first approved cardiovascular
Amgen banking on three launches in 2015

year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for
Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager / Account Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Great salary and bebefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Scientific Director: Great salary and bebefits

Senior Programme Executive: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...